About Acalabrutinib API
Therapeutic CategoryAnti-Cancer/ Oncology-es
CAS Number
870524-78-5
API Technology
Small molecule
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Under Development
Mechanism of Action
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that plays an important role in the survival and growth of B cells. By blocking BTK, acalabrutinib can help to slow down or even stop the growth of cancer cells.
Indication
The FDA approved Acalabrutinib for the treatment of adult patients with Mantle Cell Lymphoma (MCL) has received at least one prior therapy. Chronic lymphocytic leukemia (CLL). Small lymphocytic lymphoma (SLL).
Related APIs
Acalabrutinib
Anti-Cancer/ Oncology-es
Enzalutamide-es
Anti-Cancer/ Oncology-es
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!